XML 31 R20.htm IDEA: XBRL DOCUMENT

Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2019

Quarterly Financial Information Disclosure [Abstract]

NOTE 13 – QUARTERLY FINANCIAL DATA (UNAUDITED)

The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December 31, 2019. The unaudited information set forth below has been prepared on the same basis as the audited information contained herein and includes all adjustments necessary to present fairly the information set forth. The operating results for any quarter are not indicative of results for any future period. All amounts are in thousands except per share amounts.


	2019														2018
	Q1		Q2		Q3		Q4		Q1		Q2		Q3		Q4
Revenues	$	8,071	$	17,548	$	21,958	$	54,851	$	12,637	$	21,416	$	23,562	$	26,837
Operating expenses	51,968		51,052		51,206		53,382		33,634		40,556		39,803		47,609
Net (loss) income	(42,203)		(30,356)		(27,361)		4,501		(20,187)		(16,640)		(12,843)		(19,219)
Net loss attributable to non-controlling interest	(53)		(72)		(54)		(54)		—		—		—		(555)
Net (loss) income attributable to Sangamo Therapeutics, Inc.	(42,150)		(30,284)		(27,307)		4,555		(20,187)		(16,640)		(12,843)		(18,664)
Basic and diluted net (loss) income per share attributable to Sangamo Therapeutics, Inc.	(0.41)		(0.26)		(0.24)		0.04		(0.23)		(0.17)		(0.13)		(0.18)